Zarontin and Petit mal epilepsy - a phase IV clinical study of FDA data

Summary:

Petit mal epilepsy is reported as a side effect among people who take Zarontin (ethosuximide), especially for people who are female, 10-19 old, also take Lamictal, and have Seizures.

The phase IV clinical study analyzes which people have Petit mal epilepsy when taking Zarontin. It is created by eHealthMe based on reports of 958 people who have side effects when taking Zarontin from the FDA, and is updated regularly.

What is Zarontin?

Zarontin has active ingredients of ethosuximide. It is often used in petit mal seizure. eHealthMe is studying from 987 Zarontin users. Check the latest studies of Zarontin.

What is Petit mal epilepsy?

Petit mal epilepsy (absence seizure) is found to be associated with 346 drugs and 611 conditions by eHealthMe. Check the latest studies of Petit mal epilepsy.

On Jul, 11, 2026

958 people reported to have side effects when taking Zarontin.
Among them, 46 people (4.8%) have Petit mal epilepsy.

Could Zarontin cause Petit mal epilepsy?

Among these 46 people:

What is the gender of people who have Petit mal epilepsy when taking Zarontin? *

female: 52.27 %
male: 47.73 %

What is the age of people who have Petit mal epilepsy when taking Zarontin? *

What are other drugs people take besides Zarontin? *

What are other side effects people have besides Petit mal epilepsy? *

Drug Ineffective: 7 people, 15.22%
Nausea And Vomiting: 6 people, 13.04%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 5 people, 10.87%
Abdominal Pain Upper: 4 people, 8.70%
Nausea (feeling of having an urge to vomit): 3 people, 6.52%
Weight Decreased: 3 people, 6.52%
Headache (pain in head): 3 people, 6.52%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 6.52%
Itching: 3 people, 6.52%
Drowsiness: 3 people, 6.52%

What are the existing conditions these people have? *

Seizures (abnormal excessive or synchronous neuronal activity in the brain): 4 people, 8.70%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 2 people, 4.35%
Rosacea (a skin condition that causes facial redness): 1 person, 2.17%
Nasopharyngitis (inflammation of the nasopharynx): 1 person, 2.17%
Lennox-Gastaut Syndrome (epilepsy characterized by frequent seizures and different seizure types): 1 person, 2.17%
Ill-Defined Disorder: 1 person, 2.17%
Dysphemia (stammering or stuttering): 1 person, 2.17%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 2.17%
Asthma: 1 person, 2.17%
Angiomyolipoma (most common benign tumour of the kidney): 1 person, 2.17%

* Approximation only. Some reports may have incomplete information.

Do you take Zarontin and have Petit mal epilepsy?

- Check whether Petit mal epilepsy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zarontin:

Zarontin (987 reports)

Browse all side effects of Zarontin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Petit mal epilepsy:

Petit mal epilepsy (346 drugs)

Browse all the conditions that are associated with Petit mal epilepsy:

Petit mal epilepsy (611 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ethosuximide (the active ingredients of Zarontin) and Zarontin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.